# Eplerenone

## Inspra F.C. 50mg

##### 臨採

| TAH Drug Code      | [**OINS**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OINS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Congestive Heart Failure Post-Myocardial Infarction. NYHA Class 2 of Heart Failure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Dosing             | Heart failure - Myocardial infarction with complication: initial, 25 mg once daily; titration preferably within 4 weeks to 50 mg once daily. Hypertension: initial, 50 mg once daily; allow 4 weeks to achieve optimum antihypertensive effect; may increase to maximum 50 mg twice daily for inadequate response. New York Heart Association class II (chronic) heart failure: initial, 25 mg once daily, followed by an increase to 50 mg once daily after 4 weeks if potassium level no more than 5 mmol/L.                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | For All Patients with hypersensitivity to eplerenone, hyperkalemia or clinically significant hyperkalemia, serum potassium >5.0 mEq/L at initiation, creatinine clearance < or =30 mL/min, severe hepatic insufficiency (Child-Pugh class C), concomitant administration of strong CYP3A4 inhibitors, or concomitant administration of angiotensin-converting enzyme inhibitors(ACEI) or angiotensin receptor blockers(ARB). For the treatment of hypertension in patients with type 2 diabetes with microalbuminuria, serum creatinine >2.0 mg/dL in males or >1.8 mg/dL in females, creatinine clearance <50 mL/min, or concomitant administration of potassium supplements or potassium-sparing diuretics. |
| Adverse Effects    | ommon Endocrine metabolic: Hyperkalemia (3.4% ) Renal: Serum creatinine raised (2.4% ) Serious Cardiovascular: Angina pectoris, Myocardial infarction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

